Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease st udy. Lancet . 1997;349: 1269-76.
Nordst rom M, Lindblad B, Bergqvist D, Kj ellst rom T. A prospect ive study of the incidence of deep-vein thrombosis within a defi ned urban populat ion. J Intern Med. 1992;232:155-60.
Rosendaal FR. Risk factors for venous thrombosis: prevalence, risk, and interact ion. Semin Hematol. 1997;34:171-87.
Egeberg O. Thrombophilia caused by inheritable defi ciency of blood ant ithrombin. Scand J Clin Lab Invest . 1965;17:92.
Griffi n JH, Evat t B, Zimmerman TS, Kleiss AJ, Wideman C. Defi - ciency of protein C in congenital thrombot ic disease. J Clin Invest . 1981;68:1370-3.
Comp PC, Esmon CT. Recurrent venous thromboembolism in pat ients with a part ial defi ciency of protein S. N Engl J Med. 1984;311:1525-8.
Bert ina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Rode H, et al. Mutat ion in blood coagulat ion factor V associated with resistance to act ivated protein C. Nature. 1994; 369:64-7.
Poort SR, Rosendaal FR, Reitsma PH, Bert ina RM. A common genet ic variat ion in the 3′-unt ranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-703.
Frosst P, Blom HJ, Milos R, Goyet te P, Sheppard CA, Mat thews RG, et al. A candidate genet ic risk factor for vascular disease: a common mutat ion in methylenetet rahydrofolate reductase. Nat Genet . 1995;10:111-3.
De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management . Blood. 1996;87:3531-44.
D’Angelo A, Selhub J. Homocysteine and thrombot ic disease. Blood. 1997;90:1-11.
Carson NA, Cusworth DC, Dent CE, Field CM, Neill DW, Westall RG. Homocyst inuria: a new inborn error of metabolism associated with mental defi ciency. Arch Dis Child. 1963;38:425-36.
Gerrit sen T, Vaughn JG, Waisman HA. The ident if icat ion of homocysteine in the urine. Biochem Biophys Res Commun. 1962; 9:493-6.
Laster l, Mudd SH, Finkelstein JD, Irreverre F. Homocyst inuria due to cystathionine synthase defi ciency: the metabolism of l-methionine. J Clin Invest . 1965;44:1708-19.
McCully KS. Vascular pathology of homocysteinemia: implicat ions for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56:111-28.
Mudd SH, Uhlendorf BW, Freeman JM, Finkelstein JD, Shih VE. Homocyst inuria associated with decreased methylenetet rahydrofolate reductase act ivity. Biochem Biophys Res Commun. 1972;46:905-12.
St arkebaum G, Harlan JM. Endot hel ial cel l inj ury due t o copper-catalyzed hydrogen peroxide generat ion f rom homocysteine. J Clin Invest . 1986;77:1370-6.
Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, et al. Promot ion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Nat l Acad Sci U S A. 1994;91:6369-73.
Lent z SR, Sobey CG, Piegors DJ, Bhopat kar MY, Faraci FM, Malinow MR, et al. Vascular dysfunct ion in monkeys with diet - induced hyperhomocyst (e)inemia. J Clin Invest . 1996;98:24-9.
Fryer RH, Wilson BD, Gubler DB, Fit zgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces t issue factor act ivity in endothelial cells. Arterioscler Thromb. 1993;13:1327-3.
Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent , suppresses ant icoagulant heparan sulfate expression in cultured porcine aort ic endothelial cells. J Clin Invest . 1993;92:1381-6.
Stamler JS, Osborne JA, Jaraki O, Rabbani IE, Mullins M, Singel D, et al. Adverse vascular ef fects of homocysteine are modulated by endothel ium-derived relaxing factor and related oxides of nit rogen. J Clin Invest . 1993;91:308-18.
Wang J, Dudman NP, Wilcken DE. Effects of homocysteine and related compounds on prostacyclin product ion by cultured human vascular endothelial cells. Thromb Haemost . 1993;70: 1047-52.
Haj j ar KA. Homocysteine-induced modulat ion of t issue plasminogen act ivator binding to it s endothelial cell membrane receptor. J Clin Invest . 1993;91:2873-9.
Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med. 1998; 158:2101-6.
Franco RF, Araúj o AG, Guerreiro JF, Elion J, Zago MA. Analysis of the 677 C– > T mutat ion of the methylenetet rahydrofolate reductase gene in dif ferent ethnic groups. Thromb Haemost . 1998;79:119-21.
Antoniadi T, Hatzis T, Kroupis C, Economou-Petersen E, Petersen MB. Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutat ions in a Greek populat ion of blood donors. Am J Hematol. 1999;61:265-7.
Couturaud F, Oger E, Abalain JH, Chenu E, Guias B, Floch HH, et al. Methylenetet rahydrofolate reductase C677T genotype and venous thromboembolic disease. Respirat ion. 2000;67:657-1.
Brat t st rom l , Zhang Y, Hurt ig M, Refsum H, Ost ensson S, Fransson l , et al . A common met hylenet et rahydrofolat e reductase gene mutat ion and longevity. Atherosclerosis. 1998;141:315-9.
Sacchi E, Tagliabue I, Duca F, Mannucci PM. High frequency of the C677T mutat ion in the methylenetet rahydrofolate reductase (MTHFR) gene in northern Italy. Thromb Haemost . 1997;78:963-4.
Gut iérrez Revilla JI, Pérez HF, Calvo Mart ín MT, Tamparillas SM, Gracia RJ. [C677T and A1298C MTHFR polymorphisms in the et iology of neural tube defects in Spanish populat ion]. Med Clin (Barc). 2003;120:441-5.
Guillén M, Corella D, Portolés O, González JI, Mulet F, Sáiz C. Prevalence of t he met hylenet et rahydrofolat e reduct ase 677C > T mutat ion in the mediterranean Spanish populat ion. Associat ion with cardiovascular risk factors. Eur J Epidemiol. 2001;17:255-1.
Rady PL, Tyr ing SK, Hudnal l SD, Vargas T, Kel lner LH, Ni t owsky H, et al . Met hylenet et rahydrofolat e reduct ase (MTHFR): t he incidence of mut at ions C677T and A1298C in
the Ashkenazi Jewish populat ion. Am J Med Genet . 1999;86: 380-4.
Conroy JM, Trivedi G, Sovd T, Caggana M. The allele frequency of mutat ions in four genes that confer enhanced suscept ibility to venous thromboembolism in an unselected group of New York state newborns. Thromb Res. 2000;99:317-4.
Eid SS, Rihani G. Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutat ions in 200 healthy Jordanians. Clin Lab Sci. 2004;17:200-2.
Li Z, Sun l, Zhang H, Liao Y, Wang D, Zhao B, et al. Elevated plasma homocysteine was associated with hemorrhagic and ischemic st roke, but methylenetet rahydrofolate reductase gene C677T polymorphism was a risk factor for thrombot ic st roke: a mult icenter case-cont rol study in China. St roke. 2003; 34:2085-90.
Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara K, et al. Genet ic polymorphism of 5,10-methylenetet rahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulat ion. 1997;95:2032-6.
Wilcken DE, Wang XL, Sim AS, Mccredie RM. Dist ribut ion in healthy and coronary populat ions of the methylenetet rahydrofolate reductase (MTHFR) C677T mutat ion. Arterioscler Thromb Vasc Biol. 1996;16:878-82.
Arruda VR, Von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF. The mutat ion ala677– > val in the methylene tet rahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost . 1997;77:818-21.
Cat taneo M, Tsai MY, Bucciarelli P, Taioli E, Zighet t i ML, Bignell M, et al. A common mutat ion in the methylenetet rahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in pat ient s with mutant factor V (factor V:Q506). Arterioscler Thromb Vasc Biol. 1997;17:1662-6.
Brat tst röm l, Wilcken DE, Ohrvik J, Brudin l. Common methylenetet rahydrofolate reductase gene mutat ion leads to hyper homocysteinemia but not to vascular disease: the result of a meta-analysis. Circulat ion. 1998;98:2520-6.
Gohil R, Peck G, Sharma P. The genet ics of venous thromboembol ism. A met a-analysis involving ≈ 120.000 cases and 180.000 cont rols. Thromb Haemost . 2009;102:360-70.
Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002; 325:1202.
Ray JG, Shmorgun D, Chan WS. Common C677T polymorphism of the methylenetet rahydrofolate reductase gene and the risk of venous thromboembol ism: meta-analysis of 31 studies. Pathophysiol Haemost Thromb. 2002;32:51-8.
Frederiksen J, Juul K, Grande P, Jensen GB, Schroeder TV, Tybj aerg-Hansen A, et al. Methylenetet rahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospect ive and case-cont rol studies from the Copenhagen City Heart Study. Blood. 2004;104:3046-51.
Agoşton-Coldea L, Rusu ID, Bobar C, Rusu ML, Mocan T, Procopciuc IM. Recurrent thrombembolic risk in pat ients with mult iple thrombophilic disorders. Rom J Intern Med. 2008;46:261-6.
Suárez García I, Gómez Cerezo JF, Ríos Blanco JJ, Barbado FJ, Vázquez JJ. La homocisteína. ¿El factor de riesgo cardiovascular del próximo milenio? An Med Interna. 2001;18:212-4.
Keij zer MB, Borm GF, Blom HI, Bos GM, Rosendaal FR, den Heij er M. No interact ion between factor V Leiden and hyperhomocysteinemia or MTHFR 677TT genot ype in venous thrombosis. Result s of a meta-analysis of published studies and a large case-only study. Thromb Haemost . 2007;97:32-7.
González-Porras JR, García-Sanz R, Alberca I, López ML, Balanzategui A, Gut iérrez O, et al. Risk of recurrent venous thrombosis in pat ients with G20210A mutat ion in the prothrombin gene or factor V Leiden mutat ion. Blood Coagul Fibrinolysis. 2006; 17:23-8.
Ivanov P, Komsa-Penkova R, Kovacheva K, Ivanov Y, Stoyanova A, Ivanov I, et al. Impact of thrombophilic genet ic factors on pulmonary embolism: early onset and recurrent incidences. Lung. 2008;186:27-36.
Den Heij er M, Willems HPJ, Blom HJ, Gerrits WBJ, Cat taneo M, Eichinger S, et al. Homocysteine lowering by B vitamins and the secondary prevent ion of deep vein thrombosis and pulmonary embolism: a randomized, placebo-cont rolled, double-blind t rial. Blood. 2007;109:139-44.
Ray JG, Kearon C, Yi Q, Sheridan P, Lonn E; Heart out comes prevent ion evaluat ion 2 (hope-2) invest igat ors. Homocysteinelowering therapy and risk for venous thromboembolism: a rando mized t rial. Ann Intern Med. 2007;146:761-7.
Número de descargas:
2499
Número de visitas:
1274
Citas:
0
